BIOCELTIX S.A. ZY -10 (XI3) - Total Assets
Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) holds total assets worth €75.63 Million EUR (≈ $88.42 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BIOCELTIX S.A. ZY -10 - Total Assets Trend (2021–2025)
This chart illustrates how BIOCELTIX S.A. ZY -10's total assets have evolved over time, based on quarterly financial data. Also see BIOCELTIX S.A. ZY -10 stock valuation for the company's overall valuation and market capitalisation.
BIOCELTIX S.A. ZY -10 - Asset Composition Analysis
Current Asset Composition (December 2025)
BIOCELTIX S.A. ZY -10's total assets of €75.63 Million consist of 94.3% current assets and 5.7% non-current assets. Review XI3 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 90.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BIOCELTIX S.A. ZY -10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BIOCELTIX S.A. ZY -10 (XI3) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOCELTIX S.A. ZY -10's current assets represent 94.3% of total assets in 2025, an increase from 79.4% in 2021.
- Cash Position: Cash and equivalents constituted 90.4% of total assets in 2025, up from 73.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
BIOCELTIX S.A. ZY -10 Competitors by Total Assets
Key competitors of BIOCELTIX S.A. ZY -10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
BIOCELTIX S.A. ZY -10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 32.51 | 18.69 | 15.50 |
| Quick Ratio | 32.51 | 18.68 | 15.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €69.10 Million | €36.59 Million | €38.99 Million |
BIOCELTIX S.A. ZY -10 - Advanced Valuation Insights
This section examines the relationship between BIOCELTIX S.A. ZY -10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.36 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 80.7% |
| Total Assets | €75.63 Million |
| Market Capitalization | $89.73 Million USD |
Valuation Analysis
Above Book Valuation: The market values BIOCELTIX S.A. ZY -10's assets above their book value (1.19x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: BIOCELTIX S.A. ZY -10's assets grew by 80.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BIOCELTIX S.A. ZY -10 (2021–2025)
The table below shows the annual total assets of BIOCELTIX S.A. ZY -10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €75.63 Million ≈ $88.42 Million |
+80.70% |
| 2024-12-31 | €41.85 Million ≈ $48.93 Million |
+228.65% |
| 2023-12-31 | €12.74 Million ≈ $14.89 Million |
+66.40% |
| 2022-12-31 | €7.65 Million ≈ $8.95 Million |
-6.62% |
| 2021-12-31 | €8.20 Million ≈ $9.58 Million |
-- |
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more